| 引用本文: | 陈晓雨,周昕,张子豪,柳杨,杨雅茹,沈爱宗,解雪峰.头孢替安与头孢哌酮/舒巴坦应用于肾功能不全患者呼吸系统感染的药物经济学评价[J].中国现代应用药学,2020,37(6):714-718. |
| CHEN Xiaoyu,ZHOU Xin,ZHANG Zihao,LIU Yang,YANG Yaru,SHEN Aizong,XIE Xuefeng.Cefotiam and Cefoperazone/Sulbactam for Treatment of Respiratory System Infections in Renal Insufficiency Patients: Pharmacoeconomic Evaluation[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(6):714-718. |
|
| 本文已被：浏览 2600次 下载 1675次 |
码上扫一扫！ |
|
|
| 头孢替安与头孢哌酮/舒巴坦应用于肾功能不全患者呼吸系统感染的药物经济学评价 |
|
陈晓雨1, 周昕1, 张子豪1, 柳杨1, 杨雅茹2, 沈爱宗3, 解雪峰1
|
|
1.安徽医科大学, 合肥 230032;2.安徽医科大学第二附属医院, 合肥 230601;3.中国科学技术大学附属第一医院, 合肥 230001
|
|
| 摘要: |
| 目的 比较头孢替安和头孢哌酮/舒巴坦治疗肾功能不全伴呼吸系统感染患者的成本和疗效，为该类特殊人群临床合理用药提供参考。方法 回顾性统计分析安徽省3家三级甲等医院2017年1月—2017年12月肾功能不全住院患者中使用抗菌药物的情况，在综合考虑抗感染治疗效果和药品不良反应的基础上，运用最小成本分析法对用药频次前2名的头孢类药物（头孢替安vs头孢哌酮/舒巴坦）进行药物经济学评价。结果 纳入头孢替安和头孢哌酮/舒巴坦治疗的有效病例各85例。2组抗菌治疗的临床痊愈率（92.94%vs 95.29%，P=0.746）无显著性差异。住院期间均未发现明显药品不良反应，故采用最小成本分析法对2组进行成本效果分析，结果显示头孢替安组的平均直接医疗成本低于头孢哌酮/舒巴坦组（$437.46 vs$682.28，P<0.001）。结论 与头孢哌酮/舒巴坦相比，头孢替安用于治疗肾功能不全伴呼吸系统感染患者更具有经济性。 |
| 关键词: 头孢替安 头孢哌酮 肾功能不全 呼吸系统感染 药物经济学评价 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.06.015 |
| 分类号:R956 |
| 基金项目:2018年安徽省高校优秀青年人才支持计划项目（gxyq2018006）；2019年国家大学生创新创业训练计划项目（201910366042） |
|
| Cefotiam and Cefoperazone/Sulbactam for Treatment of Respiratory System Infections in Renal Insufficiency Patients: Pharmacoeconomic Evaluation |
|
CHEN Xiaoyu1, ZHOU Xin1, ZHANG Zihao1, LIU Yang1, YANG Yaru2, SHEN Aizong3, XIE Xuefeng1
|
|
1.Anhui Medical University, Hefei 230032, China;2.The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China;3.The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
|
| Abstract: |
| OBJECTIVE To evaluate the cost-effectiveness of cefotiam and cefoperazone/sulbactam in treating respiratory system infections with renal insufficiency patients and to provide reference for clinical rational use of drugs in this special group. METHODS In regard to the use of antibiotics in hospitalized patients with renal insufficiency from January 2017 to December 2017, a retrospective, multi-center cohort study was conducted in three large-scale general hospitals in Anhui province. Based on treatment effects and adverse drug reactions, cost-minimization analysis was used to evaluate the top two cephalosporins (cefotiam vs cefoperazone/sulbactam) for pharmacoeconomic evaluation. RESULTS Eighty-five patients treated with cefotiam and eighty-five with cefoperazone/sulbactam were included. There was no significant difference in the clinical effective rate between the two groups (92.94% vs 95.29%, P=0.746). No significant adverse reactions were found during hospitalization. A cost-minimization analysis was adopted for economic evaluation. Medical costs was lower in cefotiam group for respiratory system infections with renal insufficiency patients($437.46 vs $682.28, P<0.001). CONCLUSION Cefotiam is more economical than cefoperazone/sulbactam in treating respiratory system infections with renal insufficiency patients. |
| Key words: cefotiam cefoperazone renal insufficiency respiratory system infections pharmacoeconomic evaluation |
